MX389244B - Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer - Google Patents
Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancerInfo
- Publication number
- MX389244B MX389244B MX2019012847A MX2019012847A MX389244B MX 389244 B MX389244 B MX 389244B MX 2019012847 A MX2019012847 A MX 2019012847A MX 2019012847 A MX2019012847 A MX 2019012847A MX 389244 B MX389244 B MX 389244B
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- compounds
- anilinoquinazoline compounds
- anilinoquinazoline
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490859P | 2017-04-27 | 2017-04-27 | |
| PCT/EP2018/060798 WO2018197642A1 (en) | 2017-04-27 | 2018-04-26 | C5-anilinoquinazoline compounds and their use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019012847A MX2019012847A (es) | 2022-01-07 |
| MX389244B true MX389244B (es) | 2025-03-20 |
Family
ID=62091877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012847A MX389244B (es) | 2017-04-27 | 2018-04-26 | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273227B2 (enExample) |
| EP (1) | EP3615522B1 (enExample) |
| JP (1) | JP7128204B2 (enExample) |
| KR (1) | KR102603153B1 (enExample) |
| CN (1) | CN110573505B (enExample) |
| AR (1) | AR111494A1 (enExample) |
| AU (1) | AU2018259078B2 (enExample) |
| CA (1) | CA3059283A1 (enExample) |
| ES (1) | ES2888298T3 (enExample) |
| MX (1) | MX389244B (enExample) |
| RU (1) | RU2769694C2 (enExample) |
| TW (1) | TWI774758B (enExample) |
| WO (1) | WO2018197642A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018259078B2 (en) * | 2017-04-27 | 2021-10-07 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| US20210380685A1 (en) * | 2018-10-18 | 2021-12-09 | Sinomab Bioscience Limited | Methods of Treating Rheumatoid Arthritis |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| US20240034788A1 (en) * | 2020-08-20 | 2024-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Abscopal therapy for cancer |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
| JP2023542290A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| KR20230064560A (ko) * | 2021-10-29 | 2023-05-10 | 보로노이바이오 주식회사 | 퀴나졸린 유도체 화합물 및 이의 용도 |
| MX2024007044A (es) * | 2021-12-09 | 2024-09-04 | Deciphera Pharmaceuticals Llc | Compuestos heterociclicos como inhibidores de kit quinasa. |
| US20250275978A1 (en) * | 2024-03-04 | 2025-09-04 | Cardiff Oncology, Inc. | Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| EE200200119A (et) | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliini derivaadid ja nende kasutamine ravimitena |
| EP1382604B1 (en) | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivative having azolyl group and quinazoline derivative |
| TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| WO2005048953A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
| MX2007004403A (es) | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070106549A1 (en) | 2005-11-04 | 2007-05-10 | Stocking Christine A | Turnkey aviation budget management |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| WO2009140549A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
| CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| CN103254142B (zh) | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN104130200B (zh) | 2014-07-01 | 2016-04-20 | 中山大学 | 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用 |
| AU2018259078B2 (en) * | 2017-04-27 | 2021-10-07 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| US11053223B2 (en) | 2017-04-27 | 2021-07-06 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
-
2018
- 2018-04-26 AU AU2018259078A patent/AU2018259078B2/en active Active
- 2018-04-26 ES ES18721348T patent/ES2888298T3/es active Active
- 2018-04-26 JP JP2019557764A patent/JP7128204B2/ja active Active
- 2018-04-26 MX MX2019012847A patent/MX389244B/es unknown
- 2018-04-26 EP EP18721348.3A patent/EP3615522B1/en active Active
- 2018-04-26 TW TW107114297A patent/TWI774758B/zh active
- 2018-04-26 CA CA3059283A patent/CA3059283A1/en active Pending
- 2018-04-26 WO PCT/EP2018/060798 patent/WO2018197642A1/en not_active Ceased
- 2018-04-26 US US15/963,122 patent/US10273227B2/en active Active
- 2018-04-26 RU RU2019136279A patent/RU2769694C2/ru active
- 2018-04-26 KR KR1020197034070A patent/KR102603153B1/ko active Active
- 2018-04-26 CN CN201880027620.0A patent/CN110573505B/zh active Active
- 2018-04-27 AR ARP180101102A patent/AR111494A1/es active IP Right Grant
-
2019
- 2019-03-05 US US16/292,817 patent/US10829479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190263787A1 (en) | 2019-08-29 |
| US20180312490A1 (en) | 2018-11-01 |
| EP3615522B1 (en) | 2021-08-04 |
| JP2020517677A (ja) | 2020-06-18 |
| AU2018259078A1 (en) | 2019-10-17 |
| KR102603153B1 (ko) | 2023-11-15 |
| KR20190141203A (ko) | 2019-12-23 |
| JP7128204B2 (ja) | 2022-08-30 |
| AU2018259078B2 (en) | 2021-10-07 |
| BR112019022229A2 (pt) | 2020-05-12 |
| US10273227B2 (en) | 2019-04-30 |
| RU2019136279A (ru) | 2021-05-27 |
| TW201904960A (zh) | 2019-02-01 |
| CN110573505A (zh) | 2019-12-13 |
| EP3615522A1 (en) | 2020-03-04 |
| RU2019136279A3 (enExample) | 2021-05-31 |
| ES2888298T3 (es) | 2022-01-03 |
| MX2019012847A (es) | 2022-01-07 |
| CA3059283A1 (en) | 2018-11-01 |
| US10829479B2 (en) | 2020-11-10 |
| TWI774758B (zh) | 2022-08-21 |
| WO2018197642A1 (en) | 2018-11-01 |
| CN110573505B (zh) | 2023-04-11 |
| AR111494A1 (es) | 2019-07-17 |
| RU2769694C2 (ru) | 2022-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| MX372716B (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| NI201500096A (es) | Compuesto químicos | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| ECSP18056196A (es) | Derivados de indano | |
| CL2012001818A1 (es) | Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis. |